3.3.6 Safety of GLP-1 RAs in MASLD Four meta-analyses investigated the safety of GLP-1 RAs (28, 30, 33, 34)
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for several indications: type 2 diabetes management (under the brand names Ozempic and Rybelsus), chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity (under the brand name Wegovy), and in adolescents aged 12 years and older with obesity
Fewer calories means less food, and fiber-rich foods like whole grains, vegetables, and legumes are often the first casualties of a suppressed appetite
According to these findings, putatively, the neural pathway through the vagus nerve is responsible for a large part of the influence of endogenous gut-derived GLP-1 on the brain, whereas peripherally administered long-acting GLP-1 RAs act directly on brain GLP-1 RAs through the humoral pathway